Literature DB >> 15173710

Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.

Matthew H Kulke1, Robert D Odze, James D Mueller, Helen Wang, Mark Redston, Monica M Bertagnolli.   

Abstract

OBJECTIVE: Both vascular endothelial growth factor and cyclooxygenase 2 overexpression have been associated with poor prognosis in a variety of human malignancies. In this study we assessed the effect of preoperative chemotherapy and radiation on expression levels of vascular endothelial growth factor and cyclooxygenase 2 in patients with esophageal cancer and determined whether these markers were associated with treatment response and overall survival.
METHODS: Expression levels of vascular endothelial growth factor and cyclooxygenase 2 were measured in a cohort of 46 patients with esophageal cancer receiving preoperative chemoradiation followed by surgical resection. Immunohistochemical stains were performed on both pretreatment biopsy specimens and posttreatment resection specimens for each patient. Differences in vascular endothelial growth factor and cyclooxygenase 2 expression before and after treatment were measured, and pretreatment expression levels were correlated with treatment response and overall survival.
RESULTS: We found that preoperative chemotherapy and radiation induced expression of cyclooxygenase 2 in stromal cells and induced vascular endothelial growth factor expression in both tumor and stromal cells. Pretreatment vascular endothelial growth factor expression did not correlate with treatment response, and cyclooxygenase 2 expression correlated with treatment response only in the subset of patients with squamous cell carcinoma. Although patients whose tumors expressed high levels of vascular endothelial growth factor and cyclooxygenase 2 tended to have shorter overall survival times, this trend did not reach statistical significance.
CONCLUSIONS: Neither vascular endothelial growth factor nor cyclooxygenase 2 are strong predictors of treatment response and survival in patients undergoing preoperative chemoradiation for esophageal cancer. This lack of prognostic significance might be explained by changes in the expression levels of these markers during treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15173710     DOI: 10.1016/j.jtcvs.2003.12.034

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  12 in total

Review 1.  Neoadjuvant treatment of esophageal cancer.

Authors:  Nicholas P Campbell; Victoria M Villaflor
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

2.  Chemoradiotherapy for esophageal cancer.

Authors:  Geoffrey Neuner; Ashish Patel; Mohan Suntharalingam
Journal:  Gastrointest Cancer Res       Date:  2009-03

Review 3.  Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy.

Authors:  Hiroshi Okumura; Yasuto Uchikado; Tetsuro Setoyama; Masataka Matsumoto; Tetsuhiro Owaki; Sumiya Ishigami; Shoji Natsugoe
Journal:  Surg Today       Date:  2013-04-19       Impact factor: 2.549

4.  Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma.

Authors:  Geoffrey Y Ku; Manjit S Bains; Do Joong Park; Yelena Y Janjigian; Valerie W Rusch; Nabil P Rizk; Sam S Yoon; Brittanie Millang; Marinela Capanu; Karyn A Goodman; David H Ilson
Journal:  J Gastrointest Oncol       Date:  2016-12

5.  Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers.

Authors:  D G Power; D H Ilson
Journal:  Ther Adv Med Oncol       Date:  2009-11       Impact factor: 8.168

6.  Apparent diffusion coefficient correlation with oesophageal tumour stroma and angiogenesis.

Authors:  Tomoyoshi Aoyagi; Kiyohiko Shuto; Shinichi Okazumi; Kohichi Hayano; Asami Satoh; Hiroshige Saitoh; Hideaki Shimada; Yoshihiro Nabeya; Toshiki Kazama; Hisahiro Matsubara
Journal:  Eur Radiol       Date:  2012-01-19       Impact factor: 5.315

7.  Polymorphism Arg290Arg in esophageal-cancer-related gene 1 (ECRG1) is a prognostic factor for survival in esophageal cancer.

Authors:  Kai Bachmann; Shanly Shahmiri; Jussuf Kaifi; Paulus Schurr; Oliver Mann; Tamina Rawnaq; Suzette Block; Viacheslav Kalinin; Jakob R Izbicki; Tim Strate
Journal:  J Gastrointest Surg       Date:  2008-12-04       Impact factor: 3.452

8.  Genetics in the pathogenesis of esophageal cancer: possible predictive and prognostic factors.

Authors:  Daniel Vallböhmer; Jan Brabender; Ralf Metzger; Arnulf H Hölscher
Journal:  J Gastrointest Surg       Date:  2009-09-12       Impact factor: 3.452

9.  The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancer.

Authors:  Min Kyu Kang; Won Park; Yoon-La Choi; Eun Yoon Cho; Geunghwan Ahn; Heerim Nam; Seung Jae Huh; Yong Chan Ahn; Do Hoon Lim; Dong Ryul Oh; Duk Soo Bae; Byoung Gie Kim
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

10.  Vascular endothelial growth factor in children with neuroblastoma: a retrospective analysis.

Authors:  Gordana Jakovljević; Srana Culić; Jasminka Stepan; Aleksandra Bonevski; Sven Seiwerth
Journal:  J Exp Clin Cancer Res       Date:  2009-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.